How to load hemophilia B. in patients, from mild to severe forms of the disease, the economic cost of already high treatment increases significantly, according to a large retrospective study of the database.
The researchers developed four profile categories (mild, moderate, moderate-severe, and severe) for men with hemophilia B based on the frequency of bleeding events and factor IX replacement claims identified in the IBM MarketScan database (June 2011 to February 2019). The average annual health resource use (HRH) and costs were compared between 5,454 patients with hemophilia B and 1: 1 demographically matched controls.
Total health care costs increased with increasingly severe clinical profiles, with hemophilia-related treatments being the main cost factor, according to researchers. Tyler W. Buckner, MD, from the University of Colorado at Denver, Aurora, wrote in Blood advance.
This was particularly true among patients with more severe clinical profiles, who were more likely to be prophylaxis with all their associated costs.
The overall mean total cost of patients with hemophilia B during the study period was $ 201,635 versus $ 7,879 for matching controls, a difference of more than 25 times (Pg <.001). In addition, in all four categories of clinical profiles, total costs of all causes, medical costs, and pharmacy costs were significantly higher among patients with hemophilia B than matching controls (Pg <0.001 for all), the researchers added.
Annual health care costs also increased with increasing severity of clinical profiles of hemophilia B, ranging from $ 80,811 and $ 137,455 in the mild and moderate groups to $ 251,619 and $ 632,088 in the moderate groups- severe and severe, respectively.
“Hemophilia-related treatments were the main cost factor. HRU was uniformly higher among patients with hemophilia B through clinical profiles, types of medical services examined, and respect for opioid use. The significant burden shows that unmet needs remain in hemophilia B, ”the researchers concluded.
This study was supported by uniQure. Dr. Buckner has received fees or honoraria for serving on advisory boards or as a uniQure consultant. Several of the co-authors are employees of the analysis group, which received consulting fees from uniQure to conduct this study, and two of the authors are employees and hold shares in uniQure.
This article originally appeared on MDedge.com, which is part of the Medscape professional network.